老年隐源性卒中合并卵圆孔未闭的预后及试验启示
一项基于人群的前瞻性研究纳入416例隐源性TIA/非致残性卒中患者,随访5年,发现合并PFO者复发性缺血性卒中风险为2.05/100患者年,与23项研究汇总的2.00/100患者年相似。风险随队列平均年龄增加而升高,≥65岁患者PFO相关风险增加(OR 2.5)。未来针对≥60岁患者的PFO封堵试验预计每组需1080例。
要点
- PFO增加卒中复发风险仅在≥65岁人群显著(OR 2.5)。
- ≥60岁患者PFO封堵试验若检测33%相对风险降低需每组约1080例。
核心结论
- 年龄是PFO患者隐源性TIA/卒中后缺血性卒中复发的决定因素,支持在老年人群开展PFO封堵试验,但预期样本量较大。
研究设计与样本
- 前瞻性研究嵌套于2014年9月1日至2019年3月31日基于人群的Oxford Vascular Study,面对面随访5年,纳入416例隐源性TIA或非致残性卒中患者。
- 系统综述与荟萃分析纳入23项其他研究(9项试验和14项观察性研究),报告PFO患者仅药物治疗或PFO vs 无PFO的缺血性卒中复发。
- 对≥60岁患者进行未来PFO封堵试验的样本量计算。
主要发现
- 153例PFO患者(平均年龄66.7岁,52.3%男性)复发性缺血性卒中风险为2.05/100患者年,与23项研究汇总的2.00/100患者年(95%CI 1.55-2.58)相似。
- 4个平均年龄≥60岁的队列汇总缺血性卒中风险为3.27/100患者年(95%CI 2.59-4.13)。
关键数值与推荐
- ≥60岁患者PFO未封堵组假设保守的2.0/100患者年缺血性卒中风险,检测33%相对风险降低(80%把握度)预计每组需1080例。
临床怎么用
- 对≥60岁隐源性TIA/卒中合并PFO患者,应认识到年龄相关的卒中复发风险,药物治疗下风险约2-3/100患者年。
- PFO封堵在老年人群的获益尚待试验证实,临床决策需个体化并考虑未来试验证据。
局限性
- 样本量计算基于假设的2.0/100患者年风险及33%相对风险降低,可能受参数影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patent foramen ovale (PFO) closure may prevent recurrent stroke after cryptogenic transient ischemic attack (TIA) or stroke (TIA/stroke) in patients aged 60 years or younger. Patent foramen ovale is associated with cryptogenic stroke in the older population, but risk of recurrence is unknown. Data on prognosis of patients receiving medical treatment at older ages (≥60 years) are essential to justify trials of PFO closure. OBJECTIVE: To examine the age-specific risk of recurrence in patients with cryptogenic TIA/stroke with PFO. DESIGN, SETTING, AND PARTICIPANTS: A prospective study was nested in the population-based Oxford Vascular Study between September 1, 2014, and March 31, 2019, with face-to-face follow-up for 5 years. A total of 416 consecutive patients with a diagnosis of cryptogenic TIA or nondisabling stroke, screened for PFO at a rapid-access TIA/stroke clinic, were included. A systematic review and meta-analysis of cohort studies reporting on ischemic stroke recurrence after cryptogenic TIA/stroke in patients with PFO who were receiving medical therapy alone, or with PFO vs no-PFO was conducted. Sample size calculation for future trials on PFO closure was performed for patients aged 60 years or older. EXPOSURES: Patent foramen ovale and age as modifiers of risk of recurrent stroke after cryptogenic TIA/stroke in patients receiving only medical therapy. MAIN OUTCOMES AND MEASURES: Risk of ischemic stroke recurrence in patients with cryptogenic TIA/stroke and PFO receiving medical therapy only, and in patients with vs without PFO, stratified by age (<65 vs ≥65 years), as well as sample-size calculation for future trials of PFO closure in patients aged 60 years or older. RESULTS: Among the 153 Oxford Vascular Study patients with PFO (mean [SD] age, 66.7 [13.7] years; 80 [52.3%] men), recurrent ischemic stroke risk (2.05 per 100 patient-years) was similar to the pooled estimate from a systematic review of 23 other studies (9 trials and 14 observational studies) (2.00 per 100 patient-years; 95% CI, 1.55-2.58). However, there was heterogeneity between studies (P < .001 for heterogeneity), owing mainly to risk increasing with mean cohort age (meta-regression: R2 = 0.31; P = .003). In the pooled analysis of 4 studies including patients with or without PFO, increased risk of stroke recurrence with PFO was seen only at age 65 years or older (odds ratio, 2.5; 95% CI, 1.4-4.2; P = .001 for difference; P = .39 for heterogeneity). The pooled ischemic stroke risk was 3.27 per 100 patient-years (95% CI, 2.59-4.13) in 4 cohorts with mean age 60 years or older. Assuming the more conservative 2.0 per 100 patient-years ischemic stroke risk in the PFO nonclosure arms of future trials in patients aged 60 years or older, projected sample sizes were 1080 per arm for 80% power to detect a 33% relative risk reduction. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that age is a determinant of risk of ischemic stroke after cryptogenic TIA/stroke in patients with PFO, such that trials of PFO closure at older ages are justified; however, projected sample sizes are large.
引用
- Mazzucco S, Li L, Rothwell PM, et al. Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review. JAMA Neurol. 2020. PMID: 32628255. doi:10.1001/jamaneurol.2020.1948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。